drugset / Press release
Phase 3 COMPASS Study of XARELTO® (rivaroxaban) Stopping Early for Efficacy; Study Meets Primary Endpoint of Prevention of Major Adverse Cardiac Events in Patients with Coronary Artery Disease or Peripheral Artery Disease
2017-02-08 · Janssen Research & Development, LLC · original jnj.com ↗
NEWS RELEASE Phase 3 COMPASS Study of XARELTO® (rivaroxaban) Stopping Early for E cacy; Study Meets Primary Endpoint of Prevention of Major Adverse Cardiac Events in Patients with Coronary Artery Disease or Peripheral Artery Disease 2/8/2017 1
The release as fetched from its publisher. jnj.com ↗